Jeligo

Linagliptin, the active ingredient in Jeligo, is a Dipeptidyl peptidase-4 (DPP-4) inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, typically as part of a comprehensive treatment plan that includes diet and exercise.

GNH USA supplies Jeligo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin belongs to the DPP‑4 inhibitor class and is used to improve glycaemic control in diabetes.

- Type 2 diabetes mellitus: lowers blood glucose levels when combined with diet, exercise and other antidiabetic agents.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Upper respiratory tract infection: cough, sore throat, or congestion. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhoea.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting. - Severe allergic reactions: anaphylaxis, angioedema, or skin rash. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Joint pain: unexplained severe arthralgia.

Linagliptin should be used with consideration of patient‑specific factors and monitoring.

- Renal impairment: monitor renal function, although dose adjustment is not required. - Hepatic impairment: assess liver enzymes before initiation and periodically thereafter. - Cardiovascular disease: use with caution in patients with a history of heart failure. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown safety; consider discontinuation. - Store at ambient temperature: keep in the original pack, protect from moisture.

Linagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong P‑glycoprotein inducers (e.g., rifampin): may lower linagliptin exposure. - Co‑administration with other DPP‑4 inhibitors: additive effect, not recommended.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased risk of hypoglycaemia; monitor glucose levels. - Diuretics: may enhance dehydration risk; assess fluid status. - ACE inhibitors or ARBs: monitor blood pressure for additive hypotensive effect.